

- selective, quadruplex-binding inhibitor of MYC expression. *ACS Chem Biol* 2016;11:139-48.
27. Calabrese DR, Chen X, Leon EC, Gaikwad SM, Phyo Z, et al. Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex. *Nat Commun* 2018;9:4229.
 28. Grandori C, Kemp CJ. Personalized cancer models for target discovery and precision Medicine. *Trends Cancer* 2018;4:634-42.
 29. Mock B, Wax J, Clynes R, Marcu KB, Potter M. The genetics of susceptibility to RIM-induced plasmacytomagenesis. *Curr Top Microbiol Immunol* 1988;141:125-7.
 30. Misund K, Keane N, Stein CK, Asmann YW, Day G, et al. MYC dysregulation in the progression of multiple myeloma. *Leukemia* 2020;34:322-6.
 31. Kadoch C, Copeland RA, Keilhack H. PRC2 and SWI/SNF chromatin remodeling complexes in health and disease. *Biochemistry* 2016;55:1600-14.
 32. Orlando KA, Nguyen V, Raab JR, Walhart T, Weissman BE. Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities. *Expert Rev Anticancer Ther* 2019;19:375-91.
 33. Lander ES, Linton LM, Birren B, Nussbaum C, Zody MC, et al. Initial sequencing and analysis of the human genome. *Nature* 2001;409:860-921.
 34. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, et al. The sequence of the human genome. *Science* 2001;291:1304-51.
 35. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, et al. Initial genome sequencing and analysis of multiple myeloma. *Nature* 2011;471:467-72.
 36. Schürch CM, Rasche L, Frauenfeld L, Weinhold N, Fend F. A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. *Virchows Arch* 2020;476:337-51.
 37. Rustad EH, Yellapantula V, Leongamornlert D, Bolli N, Ledergor G, et al. Timing the initiation of multiple myeloma. *Nat Commun* 2020;11:1917.
 38. Maura F, Rustad EH, Boyle EM, Morgan GJ. Reconstructing the evolutionary history of multiple myeloma. *Best Pract Res Clin Haematol* 2020;33:101145.
 39. Rasche L, Kortüm KM, Raab MS, Weinhold N. The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma. *Int J Mol Sci* 2019;20:1248.
 40. Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, et al. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. *Blood Adv* 2017;2:1-9.
 41. Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. *Nat Med* 2018;24:1867-76.
 42. Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. *Nat Commun* 2019;10:3835.
 43. Lonial S, Yellapantula VD, Liang W, Kurdoglu A, Aldrich J, et al. Interim analysis of the mmrf compass trial: identification of novel rearrangements potentially associated with disease initiation and progression. *Blood* 2014;124:722.
 44. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. *Nat Rev Cancer* 2002;2:175-87.
 45. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. *Leukemia* 2007;21:529-34.
 46. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. *Cancer Cell* 2008;13:167-80.
 47. Chung WC, Kim JS, Linden M, Peng L, Van Ness B, et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. *J Clin Invest* 2004;113:1763-73.
 48. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM. Animal model of human disease. Multiple myeloma. *Am J Pathol* 1988;132:593-7.
 49. Tompkins VS, Rosean TR, Holman CJ, DeHoedt C, Olivier AK, et al. Adoptive B-cell transfer mouse model of human myeloma. *Leukemia* 2016;30:962-6.
 50. Vlummens P, De Veirman K, Menu E, De Bruyne E, Offner F, et al. The use of murine models for studying mechanistic insights of genomic instability in multiple myeloma. *Front Genet* 2019;10:740.
 51. Rajagopalan A, Wen Z, Furumo Q, Ranheim E, Finn R, et al. Mice expressing MYC and NrasQ61R in germinal center B cells develop highly aggressive multiple myeloma. *Blood* 2018;132:1006.
 52. Mitchell JS, Li N, Weinhold N, Forsti A, Ali M, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. *Nat Commun* 2016;7:12050.
 53. Morgan GJ, Johnson DC, Weinhold N, Goldschmidt H, Landgren O, et al. Inherited genetic susceptibility to multiple myeloma. *Leukemia* 2014;28:518-24.
 54. Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, et al. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. *Nat Commun* 2015;6:7213.
 55. Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. *Nat Genet* 2013;45:1221-5.
 56. Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, et al. The CCND1.c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. *Nat Genet* 2013;45:522-5.
 57. Broderick P, Chubb D, Johnson DC, Weinhold N, Försti A, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. *Nat Genet* 2011;44:58-61.

58. Chattopadhyay S, Thomsen H, Yadav P, da Silva Filho MI, Weinhold N, et al. Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma. *Commun Biol* 2019;2:89.
59. Walker BA, Wardell CP, Brioli A, Boyle E, Kaiser MF, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. *Blood Cancer J* 2014;4:e191.
60. Li ZR, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, et al. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. *Proc Natl Acad Sci USA* 2003;100:8164-9.
61. Mathsyaraja H, Freie B, Cheng PF, Babaeva E, Catchpole JT, et al. Max deletion destabilizes MYC protein and abrogates Emicro-Myc lymphomagenesis. *Genes Dev* 2019;33:1252-64.
62. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, et al. Selective inhibition of BET bromodomains. *Nature* 2010;468:1067-73.
63. Balasubramanian S, Hurley LH, Neidle S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? *Nat Rev Drug Discov* 2011;10:261-75.
64. Wang KB, Elsayed MSA, Wu G, Deng N, Cushman M, et al. Indenoisoquinoline topoisomerase inhibitors strongly bind and stabilize the MYC promoter G-quadruplex and downregulate MYC. *J Am Chem Soc* 2019;141:11059-70.